Announcing a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer


FOR IMMEDIATE RELEASE August 15, 2017 CONTACT: Samantha Cummis Addario Lung Cancer Medical Institute 650-598-2857 Samantha@LungCancerFoundation.org Susan Foreman Champions Oncology, Inc. 410-369-0365 SForeman@ChampionsOncology.com The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer SAN CARLOS, Calif. And Hackensack, … Continue reading Announcing a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer

TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation


A TP Therapeutics, Inc. drug designated TPX-0005 received FDA Orphan Drug Designation on June 27, 2017.  The first patient enrolled in March 2017 in the TPX-0005 Phase 1 clinical trial for advanced solid tumors with ROS1, ALK, and NTRK rearrangements. Here is the clinical trial listing on clinicaltrials.gov: NCT03093116:  A Study of TPX-0005 in Patients … Continue reading TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation

The Global ROS1 Initiative


The Global ROS1 Initiative is a partnership between several stakeholders interested in ROS1 positive (ROS1+) cancer (also called ROS1 rearranged or ROS1 fusion cancer): The ROS1ders, an international group of patients and carers dealing with ROS1+ cancer spread over 19 countries Patient-focused nonprofits Bonnie J. Addario Lung Cancer Foundation (ALCF) and Addario Lung Cancer Medical … Continue reading The Global ROS1 Initiative

Diagnose ROS1 – und was jetzt?


Wir ROS1-Patientinnen und -Patienten sind selten. So selten, dass wir uns fast nie auf Krankenhausfluren begegnen. Wir treffen einander nicht in der örtlichen Selbsthilfegruppe oder auf Patiententagen. Aber wir wollen uns kennenlernen, denn wir haben ein gemeinsames Schicksal – Lungenkrebs mit einer ROS1-Translokation. Und wir haben brennende Fragen: Wie geht es den anderen Betroffenen, und … Continue reading Diagnose ROS1 – und was jetzt?

ROS1 fusions rarely overlap with other oncogenes in NSCLC, study finds


This article in the May 2017 issues of the Journal of Thoracic Oncology analyzed genomic profiles of two ROS1+ non-small cell lung cancer (NSCLC) patient groups: 62 patients at Massachusetts General Hospital, and 166 patients who had been sequenced by Foundation Medicine.  The ROS1+ cancer in these patients rarely tested positive for EGFR, KRAS, or other oncogenes … Continue reading ROS1 fusions rarely overlap with other oncogenes in NSCLC, study finds